Hua Medicine (Shanghai) Ltd. (HUMDF)

Market Cap	278.25M -30.7%
Revenue (ttm)	96.34M +76.6%
Net Income	-15.87M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Open	0.3036
Previous Close	0.2935
Day's Range	0.3036 - 0.3036
52-Week Range	0.2935 - 0.5000
Beta	0.85
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 20, 2026

About Hua Medicine (Shanghai)

Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA and small molecule GLP-1 for T2D and obesity; combination with insulin to treat insulin sparing in T2D; second generation glucokinase (GK) i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2011
• Employees: 424
• Stock Exchange: OTCMKTS
• Ticker Symbol: HUMDF

Financial Performance

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 9, 2026

Data Sources Report a data error